Pranlu oral suspension is indicated for asthma and allergic rhinitis symptoms.
Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor in the human airway. It inhibits the actions of LTD4 at the CysLT1 receptor and prevents airway edema, smooth muscle contraction and enhanced secretion of thick, viscous mucus.
Child : 3.5 mg/kg bid. Max dose : 10 mg/kg/day (not exceeding 450 mg daily). Adults : Take 2 tablets (225 mg) at a time, twice a day after breakfast and dinner. The dosage may be adjusted according to your age and symptoms. Strictly follow the instructions. Use in Children & Adolescents : There was a substantial benefit of adding pranlukast to usual therapy in asthmatic children.
Headache, increased incidence of respiratory tract infection, GI disturbances, induced generalized pain, fever, myalgia and arthralgia.
Pranlukast is contraindicated in acute asthma attacks and hepatic impairment/cirrhosis.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Concurrent use with warfarin and other anticoagulants may cause an increase in prothrombin time.
Should be cautious regarding the patients with renal impairment. Possible elevations in liver enzymes can happen. Withdraw treatment in patients showing signs consistent with Churg-Strauss syndrome.